dapagliflozin
astrazeneca
['dapagliflozin']
deliver dapagliflozin reduced composite end point. mainly driven by reducing worsening of hf improved symptoms burden no attenuation in the highest lvef benefit in those with improved ef ( prior ef of &lt;40%)
#esccongress
#pharmacotherapy 
Consultant Cardiology Pharm, A Professor,NICE HF Guidelines, ESC ACNAP, AAC, NHSE, UKCPA! Comments are my own.